TopStockPicks, LLC: Added 5000 INO $2.34 for a swing long to $2.50s+ maybe $2.75

Penny Stock and Small Cap Stock Newsletter "SuperNova Elite" helped stock traders making profits of $1,550 or more on stocks like INO that are given via email, chat room and live text message alerts. Want to know how? Ask Directly to me Phone: 1-888-392-9994 - Email: editor@topstockpicks.com 

Visit Topstockpicks.com to know more!

Learn how to make profit from chart patterns and momentum trading. Get started now! Click

Top Brokers for Penny Stock Trading

Looking for a affordable broker to trade penny stocks with that won’t nickel and dime you to death? Its a question I get asked often and since my SuperNova Elite premium newsletter focuses on stocks ranging from $.001 to $5.00, a top penny stock broker is a must!

If I had to recommend one, I would start with Etrade and the reason why is simple. They have a very good “flat fee” commission which is only $9.99 OR $7.99 if you are a active trader; per trade. They don’t add on extra fees for every 1,000 shares over 10,000 for example like some brokers do.

Etrade also has whats called “Etrade Pro” and this is a software program that has a level 2 (Market Depth) a charting program, a live streaming scanner with custom features, live TV, streaming news, quotes and a whole lot more. Assuming you are somewhat active, they will give this to you for free!

Charles Schwab is another broker I would recommend taking a look at. Now I have not been with Schwab in many years but I hear they are very good now for penny stocks. They don’t “restrict” penny stocks like Ameritrade does for example, they let you trade the stock you want just like Etrade does. Their commission is also a “flat fee” and I believe it is similar to Etrade at $9.99 or $7.99

Those are my top 2 penny stock brokers and I would look strongly in to them if you are serious about making big money in the penny stock markets.

Remember, my SuperNova Elite service has been built around 16 years of trading experience for stocks under $5.00 per share and above $.001 or what most would call “small cap stocks.” We have thousands of satisfied subscribers that continue to resubscribe day after day; not to mention refer their friends and family to our service as well.

Source:-http://www.topstockpicks.com/public-category/top-brokers-for-penny-stock-trading/

3 Things EVERY ETF Investor Must Know

ETF are certainly becoming the popular choice for investors, but before engaging in this market directly there are a few things every investor should know. I will cover these essentials in a moment, but first we need to understand what ETF’s are. ETFs or Exchange Traded Funds are similar to stocks in the way that they are traded, but modeled more closely after mutual funds.

Mutual funds are great low risk vehicles, but certainly have their drawbacks. For example, did you know that you can only buy into a mutual fund at the price reflected at the close of day? And investors are not able to short sell these funds either. The introduction of ETFs provides investors with a greater deal of flexibility while maintaining the low risk appetite investors desire.

If you are new to the world of ETFs, these are just a few essentials that every investor must know.

The Demise of Leveraged ETFs

Leveraged ETFs can be a great profitable tool if you know how to use them properly, but they can be dangerous if you don’t know what you are doing. These ETFs will move two to three times its benchmark over the course of a trading day allowing investors to enhance performance. If for example the benchmark rose 1% over the course of a trading day, the leveraged ETFs would rise 2% to 3% over that same period depending on the leverage utilized.

The Problem

Leveraged ETFs are great for the intraday trader, but not for the swing or position trader. The problem is that these assets were designed to track with the daily performance of their underlying benchmark rather than the long-term performance of that benchmark. Put simply if we did the math it would be obvious that over time these leveraged ETFs will deteriorate, underperforming their benchmarks, and will ultimately head toward zero.

This is simply a word of caution for those that are considering the addition of leveraged ETFs into their long-term portfolio.

Size Matters: Liquidity is Key

There are new ETFs introduced to the market regularly, but just because they are out there doesn’t mean that as investors we should trade them. New ETFs have a tendency of going bust if they fail to gain traction in the market. Simply put if an ETF does not attract enough assets, then investors will liquidate as a means of cleaning up their portfolio; which leads to forced liquidation that causes the ETF to collapse. This is a trap that you do not want to get caught up in.

The key to selecting an ETF is looking at the dollar volume of the preferred asset to make sure that it has enough sustainable traction. Generally speaking, I look for ETF’s with at least $2 million in average daily volume to even consider it for my long-term portfolio.

Commission FREE ETFs

There are a number of brokers that have initiated commission free trading for a select grouping of ETFs, as a hook for investors. While this is certainly an enticing offer, it leads to A) overtrading and B) ignoring the liquidity of the ETF. The smaller, less liquid, ETFs generally have a larger bid/ask spread, which can increase your cost of doing business. That said, in some cases you are better off paying the commissionable fee than engaging in these ill-liquid funds.

Exchange traded funds can be a great low risk investment source as long as we are aware of the potential pitfalls. One my my objectives is to help investors navigate through these hazards. I focus on highly liquid assets and do my best to steer clear of the pitfalls. If you are looking for a guide to help you navigate through these murky waters, then JOIN US here at TopStockPicks.com!

Source:- http://www.topstockpicks.com/public-category/3-things-every-etf-investor-must-know/

Bioanalytical Systems Shares Surge after Q3 Results (BASI)

Shares of Bioanalytical Systems Inc. (NASDAQ: BASI), a contract research company providing drug discovery and development services, have surged in trading today after the company announced its financial results for the third quarter of fiscal 2013. The company returned to profitability in the third quarter as it benefited from a higher gross margin and lower operating expenses.

BASI reported third-quarter operating income of $438,000, compared to an operating loss of $540,000 reported for the same period in the previous year. This was despite the fact that BASI’s revenue for the third quarter of 2013 fell from last year.

For the quarter, BASI reported revenue of $5.6 million, compared to $7.186 million reported for the same period in the previous year. On a sequential basis though, the company’s revenue rose. In the previous quarter, the company had reported revenue of $5.156 million. BASI’s service revenue for the quarter stood at $4.156 million, down 20.1% from the same period in the previous year. On a sequential basis, service revenue rose. Service revenue in the previous quarter stood at $3.667 million. Product revenue fell 27.3% on a year-over-year basis to $1.444 million. The decline was mainly due to lower sales of the company’s Culex automated sampling systems.

The significant improvement in BASI’s bottom-line was mainly due to higher gross margin. For the quarter, the company reported gross margin of 36.3%, compared to 28.7% reported for the same period in the previous year. The company’s bottom-line also benefited from a 19.3% reduction in operating expenses.
Net income for the quarter stood at $576,000, or $0.08 per basic share and $0.07 per diluted share. For the same period in the previous year, the company had posted a net loss of $246,000, or $0.03 per basic and diluted share.

Jacqueline Lemke, President, CEO and CFO of Bioanalytical Systems, said that each of the company’s critical operating metrics, including revenue, gross margin, operating income and cash flow, improved sequentially in the third quarter compared to this year’s second quarter. Lemke noted that on the product side, as previously announced, the company is collaborating with Pinnacle Technology to create a better way to monitor glucose and with Data Sciences International to add value to its Celux system. Lemke believes that the company’s recent contract to provide IND-enabling safety and toxicology studies for NanoViricides Inc. and the preferred provider agreement with G1 Therapeutics provide a solid foundation for generating long-term growth and profitability BASI is striving for.

BASI shares have surged in trading today as investors digested the company’s quarterly results. At last check, the stock was trading 32.65% higher at $1.95 on above average volume of 355,515. BASI shares struck a 52-week high of $2.07 earlier in the day.

BASI shares have broken through some key technical levels as a result of the rally today. The stock is expected to face resistance at around $2. If it breaks through this level then the upward trend in BASI shares could continue.

View to Original post :- Click here

Cereplast Receives Major Purchase Order; Shares Surge

Cereplast Inc. (OTC: CERP), a company engaged in the development and commercialization of bio-based resins, has seen a sharp rise in its shares in trading today. The rally has been sparked after the company announced the receipt of a $1.4 million purchase order for its Biopropylene® 101.

CERP’s Biopropylene 101 is part of the Cereplast Sustainables® family of resins. The product maintains most of the desirable conventional Polypropylene properties such as chemical resistance, mold shrinkage, mold flow, surface appearance, heat deflection temperature and hinge performance. However, when compared to Polypropylene, Biopropylene provides a lower carbon footprint. Given the increasing demand for environmentally friendly products, Biopropylene has a bright outlook.

Earlier today, Cereplast announced that it received a $1.4 million purchase order for its Biopropylene 101 from Dugar Eximark Private Limited, a Hyderabad, India-based company. The company will sell the material from its existing inventory. The order will be shipped from Europe over the next 10 months.

Commenting on the purchase order, Frederic Scheer, Chairman and CEO of Cereplast, said that entering into an agreement to liquidate existing inventory is a critical milestone for the company. Scheer further said that from a financial perspective, the transaction yields strong cash flow over the next 10 months due to the sale of existing product already manufactured. He added that in the company’s continued effort to build its footprint in India, it is encouraged by the continued partnership it has built with Dugar Eximark.

While the company is building its footprint in India, it is also hoping for positive developments in other parts of the world, especially in Europe. Back in April, the Italian government signed and published a decree inflicting sanctions on bags made from traditional plastics. However, in May, the U.K. government filed an opposition with the European Union (EU), claiming that Italy was breaching EU internal market rules. This has led to some delay.

CEO Scheer noted that the passing of the September 12, 2013 date without an update from the EU has left the EU market in a state of confusion in terms of what the status of the legislation is. Scheer noted that when dealing with a governing body, delays are to be expected. However, he remains confident that there will be resolution in the near-term.

For the first half of 2013, Cereplast reported net revenue of $1.7 million, significantly above the $305,000 reported for the same period in the previous year. In fact, the company’s first half revenue is higher than the revenue reported for the whole of 2012. In 2012, CERP’s total revenue was $911,000.
CERP shares have surged in trading today. At last check, the stock was trading 26.32% higher at $0.0168 on above average volume of 30.32 million.

CERP shares have broken through their 50-day moving average in trading today as a result of the rally. The stock’s MACD has also crossed above the signal line. Both of these are strong bullish signals, and suggest that the upward momentum in CERP shares could continue, going forward.

View to Original post :- Click here

Biotechnology Stock in Focus; Geron Corporation (GERN)

Equities have edged lower in trading today as market participants remain on the sidelines amid concerns over the debt ceiling issue and uncertainty related to QE3. However, shares of Geron Corporation (NASDAQ: GERN) are continuing their upward march in trading. Shares of the biotechnology company have been having an excellent run over the past couple weeks. Based in Menlo Park, California, Geron is a clinical-stage biopharmaceutical company engaged in the development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

The company uses its proprietary nucleic acid chemistry to develop imetelstat as a short, modified oligonucleotide that is a potent and specific inhibitor of telomerase, which is a key target for anti-cancer therapeutics. Imetelstat is the first ever telomerase inhibitor to advance to clinical development.
Geron is currently conducting a Phase 2 trial to evaluate the activity of imetelstat in patients with essential thrombocythemia (ET) or polycythemia vera, who need cytoreduction and have failed or are intolerant to previous therapy or who refuse standard therapy.

In June this year, Geron had announced that updated clinical trial results from its Phase 2 trial of imetelstat in ET were presented in an oral session at the 18th Congress of the European Hematology Association in Stockholm by principal investigator of the trial Prof. Dr. med. Gabriela M. Baerlocher of the University Hospital and University of Bern, Switzerland.

Prof. Baerlocher noted that imetelstat continues to be well tolerated in the trial and with no patients on treatment losing hematologic response and molecular responses maintained in 86% of the patients, the drug also appears to have good durability of its effects on the disease.

Geron is also conducting an investigator-sponsored trial (IST) to evaluate the safety and efficacy of imetelstat in patients with myelofibrosis (MF) and to determine an appropriate dose and schedule for further evaluation. The trial was initiated by Dr. Ayalew Tefferi at Mayo Clinic in November 2012 based on data from the Phase 2 clinical trial of imetelstat in patients with ET.

Last month, Geron had also reported its second-quarter financial results. For the quarter ended June 30, 2013, GERN reported a net loss of $8.9 million, or $0.07 per share, compared to $18.3 million, or $0.14 per share reported for the same period in the previous year. The company’s net loss for the first six months of 2013 stood at $20.8 million, or $0.16 per share, compared to $37.1 million, or $0.29 per share reported for the same period in the previous year.

At the end of the second quarter of 2013, GERN had $71.6 million in cash and investments on its balance sheet.

GERN shares have been gaining momentum over the past couple of weeks. Since September 9, the stock has gained nearly 97%. In today’s trading, the stock is up 23.49% to $3.05 on above average volume of 4.31 million. The stock struck a 52-week high of $3.07 earlier in the day.
GERN shares have seen a series of higher highs in the last two weeks. The stock’s MACD chart suggests that the upward momentum could continue in the near-term. However, given the progress Geron has made in its clinical trials, the stock is an excellent play in the long-term as well.

View to Original post:- Click here

I Locked in $1,500 on This Trade and so Should You.

Welcome to the 1 Rated Penny Stock Newsletter 2 Years Running
I just locked in over $1,500 on FREE and YOU SHOULD HAVE TOO!
Remember, making money and consistent money in the stock market is all about “Timing!” You need someone like myself who knows the ebb and flow of the penny stock markets.

I just sent a “text message alert” to all my SuperNova Elite Premium members to sell FREE. I am sure you remember this alert; I gave it to you at $.21 cents per share and I just exited at $.405 avg.
If you were following my advice and put in lets say $1,000, then you too are going to walk away with $1,000 profits!

My service is real live trade alerts, real live trade educational lessons, real live chat room and for just $3 a day, you can have the ability to make easy profits as well.
SuperNova Elite Gives You
Buy and sell emailsBuy and sell text message alertsPrice of alerts $.001 to $5.00Scalp Tradesli

• Swing Trades
• Short Term Trades
• 105 Educational Video Lessons 
• Live Stock Chat Room
• 6 Moderators that specialize in a variety of areas
• Nightly Stock Scans
• Portfolio Analysis of our trades
• Weekly Seminars
• 24/7 Email Support 

and more.. I look forward to meeting you and helping you become more profitable starting tomorrow

View to Original post :- Click Here

Gulf Resources Break Through Key Technical Level

Shares of Gulf Resources Inc. (NASDAQ: GURE), a China-based manufacturer and trader of bromine and crude salt as well as a manufacturer and seller of chemical products used in oil and gas field exploration, oil field drilling, wastewater processing, papermaking chemical agents and inorganic chemicals, have risen sharply in trading today. In fact, the rally has pushed GURE shares above some key technical levels. The stock also struck a 52-week high of $2.06.

GURE shares have had an excellent run over the past month after the company reported its financial results for quarter ended June 30, 2013. For the second quarter, GURE reported net revenue of $32.9 million, up 5% on a year-over-year basis. The company attributed the year-over-year increase in revenue to the growth in its chemical products segment.

The company’s gross profit for the quarter was $9.6 million, down 3% on a year-over-year basis. Gross margin for the quarter was 29%, down from 32% reported in the second quarter of 2012.
Gulf Resources reported second-quarter income from operations of $7.4 million, compared to $7.6 million reported for the same period in the previous year. The company’s operating margin for the quarter was 22%, compared to 24% reported for the same period in the previous year. Net income for the quarter was $5.4 million, or $0.14 per share, compared to $5.7 million, or $0.16 per share reported for the same period in the previous year.

Xiaobin Liu, CEO of Gulf Resources, last month said that he is pleased that the company’s net revenue for the second quarter of 2013 increased 5% as compared with the same quarter of 2012, which is mainly due to the increased sales efforts.

Commenting on the company’s outlook, Liu said that although still impacted by China’s macro-economic conditions, some raw material prices are increasing. Liu further said that the average bromine price in the second quarter of 2013 increased to $3,084 per ton as compared to $2,954 by end of 2012. Liu also noted that crude salt price is in a steadily upward trend, and the gross margin of chemical products segment also increased to 33% in the second quarter of 2013. Liu added that the company will continually try to expand its sales markets, increase its product utilization rate and decrease management and administration expenses.
GURE shares surged to a 52-week high of $2.06 in trading today. At last check, the stock was up 17.75% to $1.99 on above average volume of 818,558. GURE shares have gained nearly 35% in the last one month.
The stock today broke through $1.80 resistance level as a result of the sharp rise. This is a strong bullish signal. The bullish trend is further confirmed by the stock’s MACD chart. GURE shares are expected to break through $2 level in the next few trading sessions.

The technical indicators for GURE suggest that the stock could see some gains in the near-term. However, GURE also looks like a good opportunity in the longer-term, given the company’s bullish outlook.
View to Original post  :- Click here

Big Mover on The Nasdaq; Towerstream Corporation (TWER)

Shares of Towerstream Corporation (NASDAQ: TWER), a provider of broadband services to commercial customers, have risen sharply in trading today. TWER shares have been boosted by M&A news in the telecom sector. The sharp rise in trading today has helped TWER shares break through some key technical levels. Technical indicators suggest that the upward momentum in TWER shares could continue.

Earlier today, two major deals were announced in the telecom sector. Verizon Communications (NYSE: VZ) announced that it will acquire Vodafone Group Plc’s (ADR) (NASDAQ: VOD) 45% stake in Verizon Wireless, the joint venture between VZ and VOD. Meanwhile, Microsoft Corp. (NASDAQ: MSFT) announced that it will acquire Nokia Corporation’s (ADR) (NYSE: NOK) handset business.

News of the deals lifted shares in the telecom sector, including those of Towerstream Corporation. However, TWER shares are also gaining as the stock’s technical indicators are giving bullish signals.

TWER shares have surged after the stock entered oversold territory recently. At last check, TWER shares were up 8.60% to $2.40 on volume of 192,643. The stock broke through $2.30 resistance level earlier in the day. It also broke through $2.40 resistance level before paring some of the gains. The stock’s MACD is about to cross over the signal line. This is a strong bullish signal. In addition, the stock is also about to establish a “golden cross”, with the 50-day moving average about to cross the 200-day moving average.

Once the 50-day moving average crosses the 200-day moving average, there could be significant gains.
TWER shares could break through $2.40 and $2.50 resistance levels in the next few trading sessions. TWER shares could see a pullback from around $2.70. Certainly, there is significant upside potential from current level.

Last month, Towerstream had reported its financial results for the second quarter ended June 30, 2013. For the quarter, the company reported revenue of $8.21 million, compared to $8.10 million reported for the same period in the previous year. The company’s consolidated gross margin for the quarter was 35%, compared to 54% reported for the same period in the previous year. Churn rate was 2.37% during the second quarter of 2013, compared to 1.65% reported for the same period in the previous year. ARPU stood at $740, compared to $708.

At the end of second quarter of 2013, the company signed a long-term Wi-Fi lease agreement with a major cable operator. Jeffrey Thompson, President and CEO of Towerstream, said that securing the first anchor tenant for TWER’s neutral host network is a major milestone and validates the company’s rent-based business model. Thompson further said that the company expects to continue to expand its Wi-Fi customer base over the balance of the year, while preparing for the impending rollout of small cell.

According to Joseph Hernon, CFO of Towerstream, small cell technologies, including Wi-Fi, will allow service providers and platform players to differentiate their offering, add new services, and improve the user experience in dense urban markets where demand levels are pressuring network capacity.

View to Original post :- Click Here

Smaller Trading Account, Check out This Service

Welcome to the #1 Rated Penny Stock Newsletter 2 Years Running

Hello Traders, Just a FYI 12 hours left to SAVE $150 off SuperNova Elite before prices rise. (click here for full description of service and price details) One of the most commonly asked questions I get from the Free List is “Can I use just $500 or $1,000 with your service?

Listen, I totally understand that money is tight now days but you want a service that will work for your smaller account. Well, listen to the comment from Sharon which she just posted to me in the chat room.
Jeff, I would like to quickly thank you before I leave for the evening. I have checked out many services but none of them worked for my trading account. I only had about $600 to start with and while other services were making big profits, it wouldn’t equal ANY profit for my smaller account size. Anyway, I decided to join and today alone, my trading account went from $600 to $870 dollars due to your AMBS text message alert. Now my focus will be on a smaller percent gain due to my larger bank roll.

 I am so happy I found your service and I look forward to being with you a long time. Enjoy your family and extra day off, you deserve it!

Well there ya go! The point is, YES I know of other services out there that are awesome for bigger accounts, but MY SuperNova Elite service works BEST for traders from $500 to $50,000 accounts.
If you have a $500 account you can focus on my $.001 to $.10 cent stocks – which see the biggest % gains.
If you have a $5,000 to $50,000 account you can pretty much play ALL my trades under $5.00 – solid gains but bigger profits with larger position size!

Listen, the longer you sit and watch the more profits you miss. I am here to help you not only make MORE profits but to LEARN why you are making all this extra cash. If I can teach you how and why we are making trades, then you can start to duplicate it on your own!

SuperNova Elite Gives You Buy and sell emails Buy and sell text message alerts Price of alerts $.001 to $5.00 Scalp Trades Swing Trades Short Term Trades 105 Educational Video Lessons – More learning material than any other service Live Stock Chat Room 6 Moderators that specialize in a variety of areas Nightly Stock Scans Portfolio Analysis of our trades Weekly Seminars 24/7 Email Support
View to Original post :- Click Here

Turn $4,000 into $25,000, Let Me Show You How

Hello Penny Stock Traders, The question I get from most people who inquire about my SuperNova Elite service is “Can I take $5,000 and turn it into $25,000 or more trading penny stocks?” The answer simply is YES. Why do I say that you ask? Well, I have members who do it all the time. As a matter of fact,

I have had several members accomplish this $25,000 goal just by using my Premium services they get with the SuperNova Elite newsletter. Just take a look at what Royal told me yesterday….. “Jeff, in just over 8 months I took a $4,200 account and turned it over $25,000 following your trade alerts and also making my own trades which I learned how to do from your educational videos.

I couldn’t have done this without your service. – Royal 8/26″ Listen, my service is second to none when it comes to educational learning material, volatile and profitable alerts and spoon feeding you buy and sell email and text messages. As a matter of fact, our Premium Chat Room is the largest for penny stocks on the Net today. SuperNova Elite Gives You Buy and sell emails Buy and sell text message alerts Price of alerts $.001 to $5.00 Scalp Trades Swing Trades Short Term Trades 105 Educational Video Lessons – More learning material than any other service Live Stock Chat Room 6 Moderators that specialize in a variety of areas Nightly Stock Scans Portfolio Analysis of our trades Weekly Seminars 24/7 Email Support

View to Original post :- Click Here

Big Mover on the Nasdaq; Genetic Technologies Limited (GENE)

U.S. equity market has rebounded sharply in trading today as market sentiment has been lifted by some positive economic data from Europe and China. All three major indexes have risen sharply. Among the biggest gainers on the Nasdaq today is Genetic Technologies Limited (ADR) (NASDAQ: GENE), an Australia-based company providing genetic testing services.

GENE shares are surging after the company today said that its wholly-owned subsidiary Phenogen Sciences Inc. executed an agreement with InterWest Health of Missoula, Montana, U.S. to use the InterWest provider network. A regional provider, InterWest Health services seven states in north-west U.S. The states include Montana, Idaho and Washington.

 This is the eighth such agreement executed between GENE and similar U.S. Preferred Provider Organizations (PPOs). Apart from InterWest Health, the company has executed agreements with FedMed Inc., MultiPlan Network, Three Rivers Provider Network, Prime Health Services, National Preferred Provider Network/PlanCare America/Ohio Preferred Network LLC, Galaxy Health Network and Fortified Provider Network. These agreements are certainly benefiting GENE as evidenced by the company’s performance during the quarter ended June 30, 2013. During the quarter, the company received a record number of BREVAGen™ test samples. Total patient samples received during the quarter stood at 599, which represents growth of over 48% on a quarter-over-quarter basis.

 For the first six months of 2013, total BREVAGen™ test samples received stood at 1,547, which represents a growth of over 272% on a year-over-year basis.

 GENE, recently, also executed a merger agreement with Sydney-based Simavita Holdings Limited. The agreement was executed by the company’s Canadian-listed subsidiary, Gtech International Resources Limited. Gene Technologies CEO Alison Mew said that the company is extremely pleased that Gtech entered into a transaction that will see all of its shareholders, including GENE, benefit from the planned expansion of the exciting Simavita business into the huge North American market and beyond. Mew also said that the transition of management to the incoming Simavita team will allow Genetic Technologies to maintain focus on the expansion of its U.S. business through the growth of its flagship BREVAGen™ test.

Apart from these positive developments, GENE is also expected to benefit from an increase in demand for genetic testing. According to a study conducted by the research arm of UnitedHealth Group, spending on genetic testing in the U.S. alone is expected to be between $15 billion and $25 billion by 2021. UnitedHealth expects double digit growth over the next few years. GENE, with its recent developments, is certainly well-positioned to capitalize on this growth. Not surprisingly, the company’s shares have been seeing increasing interest from investors.

 GENE shares have surged in trading today, striking an intra-day high of $2.81. At last check, the stock was trading 24.09% higher at $2.73. The rally today has pushed GENE shares above their 50-and 200-day moving averages, which is a strong bullish signal. The bullish trend is further confirmed by the MACD chart. The MACD has crossed over the signal line. GENE shares are expected to face resistance at around $2.80. If the stock breaks through this level then the next resistance level will be at around $3.
View to Original post :- Click Here

Will the Pullback in Equities Continue?

On Friday, U.S. equity market slipped, with all three benchmark index ending the day in red. Stocks also fell for the week. The pullback last week has prompted investors to ask the question whether the rally in U.S. 
equity market is coming to an end. In an interview with CNBC last week, Marc Faber said that he expects a 1987 like crash in equities in the second half of the year.

Faber is not the only one expecting a pullback right now. Speaking to CNBC, John Stoltzfus, Chief Investment Strategist at Oppenheimer, said that there is a considerable opportunity for profit taking given that the market is still not certain about the timing of the Federal Reserve’s plans to scale back its bond purchase program.

 While the broader market struggled last week, basic materials sector enjoyed an excellent run as some robust economic data from China lifted investors’ sentiment on commodities. Copper prices rose sharply last week. Shares of mining giants such as BHP Billiton (ADR) (NYSE: BHP), and Rio Tinto Plc (ADR) (NYSE: RIO). It will be interesting to see if the sector can continue its excellent run amid signs of improvement in the Chinese economy.
 Original Post :- View to Original post Click here

Apple to Launch Next Generation of iPhone Next Month

According to a report from All Things D, technology giant Apple Inc. (NASDAQ: AAPL) is expected to launch its next-generation iPhone on September 10. The report was also confirmed by USA Today. However, a spokeswoman for Apple denied the report, saying the company does not comment on rumors. The next generation iPhone from Apple will be keenly watched as the Cupertino, California-based company has been facing increasing competition from Samsung lately.

 Apple shares, which struck an all-time high of $705.07 in September last year, have struggled since last October. It will be interesting to see if the next generation iPhone can give the company’s shares a boost. Apple is not the only smartphone maker in news today.

BlackBerry Ltd. (NASDAQ: BBRY) is also expected to remain in focus today after the struggling company said that it has set up committee to look at its strategic options, which include a possible sale. BBRY once dominated the smartphone market; however, in the last three years the company has struggled to compete against the likes of iPhone and Android-operated phones. Reports of BBRY considering a possible sale first appeared on Friday, following which the stock surged more than 9%.

Original Post :- View to Original post Click here

Automakers Near 52-Week High

U.S. automakers Ford Motor Company (NYSE: F) and General Motors Company (NYSE: GM) are hovering around their 52-week high as improving U.S. auto sales are continuing to benefit the two companies. Last week, a report showed that auto sales rose to pre-crisis level in the month of July. Both Ford and GM registered a sharp rise in July U.S. auto sales

While Ford registered an 11% increase in U.S. auto sales, GM posted a 16% increase in sales. More importantly, the outlook for U.S. auto sales remains robust.One of the major factors behind improving auto sales has been increasing demand for pickup trucks, which is being driven by an ongoing improvement in the economy.

Last week, a data from the Commerce Department showed that the U.S. economy grew more than forecast in the second quarter of 2013, while manufacturing activity accelerated in the month of July.
 The big question is whether you should buy automakers at current levels. The answer is probably yes as the recovery in the auto market is expected to continue, benefiting both Ford and GM. In terms of valuation, both Ford and GM are looking attractive right. Ford is trading on a P/E ratio of just 11.52, while GM is currently trading on a P/E ratio of 13.25. Given these factors, there is certainly further upside potential in automaker
 Original post :- Click here